LEO Pharma
LEO Pharma is a foundation-owned Danish dermatology company whose cancer-related trials concern actinic keratosis, the precancerous skin lesion that can progress to squamous cell carcinoma.
Overview
LEO Pharma, based in Ballerup near Copenhagen and majority-owned by the LEO Foundation, specialises in medical dermatology. Its registry footprint in cancer comes from actinic keratosis, the sun-damage lesion that can progress to cutaneous squamous cell carcinoma: it marketed ingenol mebutate gel (Picato) for the condition until the product's EU authorisation was withdrawn in 2020 over a possible skin cancer signal. OnCo records it so that those phase 3 trials resolve to a sponsor page.
Similar pages
not linked directly; found by shared links- CompanyAlmirall
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyGalderma
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.